Trials / Not Yet Recruiting

Not Yet RecruitingNCT07279584

Golidocitinib Combined With GemOx in RR PTCL

An Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Golidocitinib Combined With GemOx in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma

Status: Not Yet Recruiting
Phase: Phase 2
Study type: Interventional
Enrollment: 31 (estimated)

Sponsor: Ruijin Hospital · Academic / Other
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

The objective of this study is to evaluate the efficacy and safety of golidocitinib in combination with the GemOx regimen in r/r PTCL

Conditions

Peripheral T-cell Lymphomas (PTCL)

Interventions

Type	Name	Description
DRUG	golidocitinib	150mg qd po
DRUG	GEMOX	Gemcitabine: 1000mg/m2, d1; Oxaliplatin:100mg/m2, d1

Timeline

Start date: 2025-12-20
Primary completion: 2026-12-31
Completion: 2027-12-31
First posted: 2025-12-12
Last updated: 2025-12-12

Source: ClinicalTrials.gov record NCT07279584. Inclusion in this directory is not an endorsement.